Bharat Parenterals gets license and authorization for Favipiravir oral suspension for Covid treatment
Bharat Parenterals said that it has secured the license and authorization from Drugs Controller General of India (DCGI) and Central Drugs Standard Control Organisation (CDSCO) for the manufacturing and marketing of Favipiravir oral suspension l00mg/ml for the treatment of Covid-19.
The Gujarat-based pharma company said that the product patent for its Favipiravir oral suspension l00mg/ml has already been filed under fast track approval.
Bharat Parenterals said that it is the first in the Indian market to get the license and authorization for manufacturing and commercializing the Covid-19 treatment.
Earlier this month, Vivimed Labs launched Favulous, a generic version of Covid-19 drug Favipiravir Tablet 200 mg and 400 mg in India.